Sunshine Biopharma Inc.

Listed Company

SBFMCIK 0001402328NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsColoradoFY ends Dec 31

Period

FY 2025

Revenue

$36.31M

Net Income

$-5.98M

Total Assets

$30.08M

Equity

$23.04M

Shares Out

5.01M

Op. Cash Flow

$-5.33M

SBFM$1.81+14.56% · past yearDBEQ Basic

Daily closing prices

Business

Sunshine Biopharma is a pharmaceutical company operating as a downstream generic-drug distributor and OTC product seller in Canada. Through subsidiary Nora Pharma, it acquires rights to market generic drugs via in-licensing and distribution agreements. The company also develops OTC supplements through Sunshine Canada and conducts proprietary research on oncology and antiviral candidates including K1.1 mRNA and SBFM-PL4. Products are distributed to Canadian pharmacies and previously to U.S. markets.

Summary from 10-K filed 2026-04-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue:	36	35	24	4	228,426
Cost of Sales	24	24	16	3	117,830
Gross profit	12	11	8	2	110,596
Accounting	698,083	967,614	463,705	341,139	118,423
Consulting	2	925,188	850,173	—	—
Director fees	400,000	400,000	400,000	300,000	0
Intangible assets impairment	2	0	—	—	—
Legal	385,142	875,698	512,199	550,117	232,616
Marketing	1	940,278	734,248	578,085	0
Office	4	3	2	—	—
R&D	604,308	933,902	2	811,858	672,209
Salaries	7	8	6	6	1
Taxes	469,305	387,005	289,737	55,233	—
Depreciation & amortization	332,070	223,527	149,147	—	—
Total General & Administrative Expenses	18	16	13	29	3
(Loss) from operations	−6	−6	−5	−27	−2
Foreign exchange gain (loss)	2,642	−44,082	−245	−476	50
Interest income	280,901	496,003	811,974	518,650	0
Interest expense	0	−8,774	−137,308	—	—
Gain (Loss) on asset sale	−10,257	0	—	—	—
Total Other Income (Expense)	273,286	443,147	674,421	489,614	−10
Net (loss) before income taxes	−6	−5	−4	−27	−12
Provision for income taxes	21,609	−234,858	395,166	233,304	0
Net (Loss)	−6	−5	−5	−27	−12
Gain (Loss) from foreign exchange translation	764,650	−2	534,258	184,986	−20,268
Comprehensive (Loss)	−5	−7	−4	−27	−12
(Loss) per common share, Basic	−1.44	−7.32	−351.36	−1.76	−4.76
Weighted average common shares outstanding, Basic	4	701,749	12,825	15	3

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	9	10	16	22	2
Accounts receivable	3	4	3	2	7,798
Inventory	13	11	6	3	105,650
Prepaid expenses	798,384	1	310,591	283,799	29,625
Total Current Assets	27	26	25	27	2
Property & equipment	557,370	546,055	365,868	394,249	7,061
Intangible assets	2	3	1	776,856	0
Deferred tax asset	0	92,234	0	—	—
Right-of-use-asset	778,846	936,037	646,779	760,409	0
Total Long-Term Assets	3	5	2	—	—
TOTAL ASSETS	30	31	27	29	2
Accounts payable & accrued expenses	6	6	3	3	42,942
Earnout payable	295,797	295,797	3	4	0
Income tax payable	268,276	268,276	299,869	373,191	0
Current portion - right-of-use-liability	215,637	207,756	118,670	123,026	0
Total Current Liabilities	6	6	6	7	91,229
Right-of-use-liability	596,785	744,724	539,035	642,232	0
Total Long-Term Liabilities	596,785	744,724	587,764	685,264	2
TOTAL LIABILITIES	7	7	6	8	2
Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 130,000 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	13,000	13,000	1,000	1,000	100,000
Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 4,905,945 and 2,580,098 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	4,905	2,580	14	22,585	2,591
Capital paid in excess of par value	98	93	84	81	33
Accumulated comprehensive income	−65,309	−829,959	696,105	161,847	−23,139
Accumulated (Deficit)	−75	−69	−64	−59	−33
TOTAL SHAREHOLDERS' EQUITY	23	24	21	22	211,662
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	30	31	27	29	2

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Disposal of tangible assets	10,257	0	—	—	—
Stock issued for services	0	12,000	0	0	918,000
Accounts receivable	−116,173	−2	−594,141	−524,486	−5,882
Inventory	−2	−6	−2	42,983	−81,879
Prepaid expenses	480,798	−207,167	−21,143	82,846	−26,847
Right-of-use asset	203,836	−341,534	131,949	—	—
Accounts Payable & accrued expenses	−189,956	4	−1	3	−18,156
Lease liability	−187,523	347,935	—	—	—
Earn-out payable	0	−2	0	—	—
Income tax payable	0	−812,080	−73,247	238,679	0
Net Cash Flows (Used In) Operating Activities	−5	−13	−9	−5	−2
Purchase of intangible assets	−661,815	−322,258	−705,848	−111,015	0
Purchase of equipment	−174,491	−2	−82,251	−193,982	0
Net Cash Flows (Used In) Investing Activities	−836,306	−2	−656,150	−15	0
Proceeds from public offering net (common stock)	2	9	4	30	0
Exercise of warrants	3	4	3,502	13	0
Purchase of treasury stock	0	−3	−541,143	—	—
Net Cash Flows Provided by Financing Activities	5	9	3	39	3
Net (decrease) in cash and cash equivalents	−1	−6	−6	20	1
Foreign currency translation adjustment	855,750	−1	534,258	184,986	−20,268
Cash paid for income taxes	0	582,483	0	0	0
Cash paid for interest	0	8,126	0	48,287	38,117
Stock issued for services	0	12,000	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Sunshine Biopharma Inc.'s CIK number?

Sunshine Biopharma Inc.'s SEC CIK number is 0001402328 (1402328). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Sunshine Biopharma Inc.'s SEC filings?

All of Sunshine Biopharma Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Sunshine Biopharma Inc. last report earnings?

Sunshine Biopharma Inc. (SBFM) most recently filed an earnings 8-K with the SEC on Apr 9, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001683168-26-002781). This is Sunshine Biopharma Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Sunshine Biopharma Inc.'s most recent earnings 8-K?

Sunshine Biopharma Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 9, 2026 under accession 0001683168-26-002781. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Sunshine Biopharma Inc.'s latest earnings 8-K →
Look up any company's CIK number →